DOI [Teaser] Key Summary Points Real-life studies on the clinical impact of neutralizing TNFi anti-drug antibodies (nADAb) including a broad range of disease activity metrics are needed, as well as studies exploring the impact of smoking on formation of nADAb.

Among people with rheumatic and musculoskeletal diseases, levels of antibodies against SARS-CoV-2 decrease in the 6-month period following two doses of mRNA vaccines, but remain above the threshold of predicted neutralizing ability in the majority of patients, research suggests.

Study findings suggest that mRNA COVID-19 vaccines have a favorable short-term safety profile in people with antiphospholipid antibodies.

Anti-carbamylated vimentin antibodies may be associated with treatment response and structural damage progression among patients with rheumatoid arthritis, shows a post-hoc analysis of data from the phase 3 RA-BEGIN trial.

Latika Gupta and Rohit Aggarwal evaluate the use of myositis-specific antibodies in the classification and management of this disease.

The development of antidrug antibodies against adalimumab or infliximab, but not etanercept, may play a role in the development of secondary treatment failure among patients with rheumatoid arthritis or spondyloarthritis, researchers report.

Antifibrillar collagen type II antibodies are associated with a favorable inflammatory outcome among patients with rheumatoid arthritis, researchers report.

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Specifically, they say that rituximab-treated patients with B-cell numbers below 10 cells/µL had “substantially diminished” circulating T follicular helper cell-like CD4+ T cells, reduced activated CD4+ CD8+ T cells with co-expression of CD38 and HLA-DR, and impaired interferon-gamma secretion by spike-specific CD4+ T cells.

3–9 November: Keep up with the latest news and interviews from the conference.

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.